VC Catalog · venture ecosystem research library
VC Catalog home Beta

Company

Linnaeus Tx

Rocket Ship RatingBased on the data VC Catalog holds.

Rocket Ship Rating: 75 out of 100

Developing LNS8801, a first-in-class GPER agonist for cancer, cardiometabolic disease, and healthy aging.

  • Biotech & therapeutics
Open relationship map
Claim, correct or request removal

Record updated 28 September 2026

About

Linnaeus Therapeutics is developing LNS8801, a first-in-class GPER agonist that treats cancer and cardiometabolic disease and aims to extend healthy aging by harnessing estrogen biology without systemic hormonal therapy.

Loading relationship preview

Cookies on VC Catalog

We use necessary cookies to run the site (sign-in, security, remembering this choice). With your permission we also use Google Analytics to understand how the site is used. Analytics cookies are set only if you accept all cookies. Privacy policy